Biosimilars Canada, the national association representing Canada’s biosimilar pharmaceutical industry, is an initiative by the Government of Newfoundland and Labrador to expand the use of biosimilar biologics in public medicine programs. We welcome the announcement that we are implementing a “switch” or transition policy.
Biopharmaceuticals have revolutionized the treatment of many life-threatening disorders. However, it can be costly…
This article is accessible to registered users. Sign up for free to read more. A free trial gives him one week access to exclusive features, interviews, summaries and commentary from the sharpest minds in the pharma and biotech space. If you have already registered as a user, please log in. If your trial has expired, you can subscribe here.
Try before you buy
• All the news that makes a difference in pharma and biotech.
• Exclusive features, podcasts, interviews, data analysis and commentary from our global network of life science reporters.
• Receive free daily breaking news from The Pharma Letter forever.
become a subscriber
• Unrestricted access to industry-leading news, commentary and analysis in pharma and biotech.
• Latest information from clinical trials, conferences, M&A, licensing, funding, regulation, patents and law, board appointments, commercial strategy and financial results.
• A daily roundup of important events in pharma and biotechnology.
• Monthly in-depth briefings on board appointments and M&A news.
• Choose from cost-effective annual packages or flexible monthly subscriptions.
